Biovista Inc. (Biovista) is a privately held drug development services provider and offers several drug development services including drug repositioning services, meta review & gap analysis, disease cohort identification services and adverse event analysis. The company offers drug repositioning services in the areas of eye related disorders, metabolic disorders such as diabetes and obesity, CNS disorders and oncology. Biovista offers its services to several pharmaceutical and biotechnology companies, academic institutions, and research and government organizations. The company has undertaken several strategic partnerships and collaboration programs with industries major companies and organizations to deliver effective services and products to its customers. Biovista operations are spread over the markets of the US, European Union and Asia. Recently, the company announced to Collaborate with U.S. Food and Drug Administration on a Medication Safety Initiative. Under this collaboration, FDA has licensed its technology platform to help analyze, identify, and better understand the way certain drugs can cause harmful side effects. Biovista is headquartered at Charlottesville in Virginia, the US.